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Abstract
Both metabolomic and genomic approaches are valuable for risk analysis, however typical approaches
evaluating differences in means do not model the changes well. Gene polymorphisms that alter function
would appear as distinct populations, or metabotypes, from the predominant one, in which case risk is
revealed as changed mixing proportions between control and case samples. Here we validate a model
accounting for mixed populations using biomarkers of fatty acid metabolism derived from a case/control
study of acute coronary syndrome subjects in which both metabolomic and genomic approaches have been
used previously. We first used simulated data to show improved power and sensitivity in the approach
compared to classic approaches. We then used the metabolic biomarkers to test for evidence of distinct
metabotypes and different proportions among cases and controls. In simulation, our model outperformed all
other approaches including Mann-Whitney, t-tests, and χ2. Using real data, we found distinct metabotypes of
six of the seven activities tested, and different mixing proportions in five of the six activity biomarkers: D9D,
ELOVL6, ELOVL5, FADS1, and Sprecher pathway chain shortening (SCS). High activity metabotypes of
non-essential fatty acids and SCS decreased odds for acute coronary syndrome (ACS), however high activity
metabotypes of 20-carbon fatty acid synthesis increased odds. Our study validates an approach that accounts
for both metabolomic and genomic theory by demonstrating improved sensitivity and specificity, better
performance in real world data, and more straightforward interpretability.
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Significance:  
This study formulates a novel test that better reflects how distributions would appear in samples having 
variance resulting from both genetic and environmental sources.  The means-testing hypothesis is replaced 
with a test for different mixing proportions in muli-modal distributions.  The study demonstrates superior 
test performance with simulated data.  Estimates of enzyme activity from real world data are demonstrated 
to better conform to the hypothesized multi-modal distributions and differences between control subjects 




Both metabolomic and genomic approaches are valuable for risk analysis, however typical approaches 
evaluating differences in means do not model the changes well.  Gene polymorphisms that alter function 
would appear as distinct populations, or metabotypes, from the predominant one, in which case risk is 
revealed as changed mixing proportions between control and case samples.  Here we validate a model 
accounting for mixed populations using biomarkers of fatty acid metabolism derived from a case/control 
study of acute coronary syndrome subjects in which both metabolomic and genomic approaches have been 
used previously.  We first used simulated data to show improved power and sensitivity in the approach 
compared to classic approaches.  We then used the metabolic biomarkers to test for evidence of distinct 
metabotypes and different proportions among cases and controls.   In simulation, our model outperformed 
all other approaches including Mann-Whitney, t-tests, and χ2.  Using real data, we found distinct 
metabotypes of six of the seven activities tested, and different mixing proportions in five of the six activity 
biomarkers: D9D, ELOVL6, ELOVL5, FADS1, and Sprecher pathway chain shortening (SCS).  High 
activity metabotypes of non-essential fatty acids and SCS decreased odds for acute coronary syndrome 
(ACS), however high activity metabotypes of 20-carbon fatty acid synthesis increased odds.  Our study 
validates an approach that accounts for both metabolomic and genomic theory by demonstrating improved 
sensitivity and specificity, better performance in real world data, and more straightforward interpretability.  
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Introduction:   
Improving risk prediction is increasingly important for early intervention and prevention.  Several 
well known risk prediction algorithms are employed – such as the Prospective Cardiovascular Munster 
(PROCAM) study(1), the 3
rd
 Joint European Task Force [Systematic Coronary Risk Evaluation 
(SCORE)](2), the Atherosclerosis Risk in Communities (ARIC) study(3), the Reynolds Risk Score(4, 5) 
and finally, the original and most widely used system, the Framingham Risk Score(6, 7)  The last was 
designed to predict the 10-year risk for major coronary events, and it does so with a c-statistic [area under 
the receiver operating characteristic (ROC) curve] of 0.7-0.8(3, 6, 7). All of these prediction algorithms 
generally include the following standard risk factors: age, sex, total (or low-density lipoprotein) 
cholesterol (C), high-density lipoprotein C (HDL-C), blood pressure, and both smoking and diabetes 
status.  Despite the utility of standard factors in coronary heart disease (CHD) risk estimation, there 
remains an intense interest in finding additional markers that would improve upon this standard(8-10); 
however, while a number of putative risk factors have been tested, few have added meaningfully(11, 12).  
Surprisingly, a relationship between leading gene variants related to classical risk markers for acute 
coronary syndrome was not validated in the data used here (13), demonstrating the challenges in this 
endeavor.  To date such analyses have rarely considered fatty acid metabolism, however we have 
demonstrated that models based on the erythrocyte fatty-acid profiles can outperform classic risk models 
in case/control discrimination (14).  Here we considered how we could employ an approach that jointly 
emphasizes the impact of genetic variance on metabolomic datasets.   
A typical approach to comparison of phenotypes across case-control populations is to compare the 
component means using methods like the two-sample t-test (with or without pooled variance) and 
generalizations of these approaches in a regression framework.  In case/control settings this translates into 
testing for evidence of a shift in the means between the two components, with the hypothesis that δ≠0, 
where μCase= μControl+δ (illustrated in Figure 1A).  However considering the metabolic mechanisms that 
give rise to the relative abundances of fatty acids – e.g. genes, diet, and lifestyle patterns – testing for a 
difference in means may not be optimal, since what appears to be a shift in means could actually be a shift 
in the relative abundance of distinct metabotypes, or metabolic phenotypes in the study case vs. control 
populations.  While the term is most commonly applied to arrays comprising multiple metabolites that 
together represent a “readout of the metabolic state”(15), here we consider the concept of a metabotype as 
a phenotypic variation within a single biomarker of enzymatic behavior, or activity.  Thus, functionally 
distinct genotypes should give rise to distinct metabotypes in large population samples.  For example, 
delta-9 desaturase (D9D) is a critical step in desaturation of 16-carbon and 18-carbon fatty acids.  It is 
4 
critical in the synthesis of palmitoleic and oleic acids from palmitic and stearic acids respectively.  In vivo, 
this activity can be estimated by the palmitoleic to palmitic acid or the oleic acid: stearic acid ratio 
(OA:SA)(16).  In a population with two D9D genotypes, having unique activities (km, bmax), each 
genotype would define a unique OA:SA mean with variance around the mean determined by diet, lifestyle 
and other environmental factors.  Figure 1B shows how two D9D populations with unique means (μ) and 
variance (2) would appear in a population sample. 
In this case, a simple comparison of the means is likely to ignore the underlying biological cause: that the 
observed (marginal) distribution of fatty-acid levels in the case and control samples, respectively, 
represent a mixture of two or more underlying distributions, or components, derived from each genetically 
determined metabotype.   
In this paper we propose a likelihood ratio test (LRT) method for testing case-control metabotype 
differences.  The test estimates the metabotype mean of each sample, and then tests for differences in the 
relative frequencies of the metabotypes in the case-control samples. We compare the proposed LRT 
method to means testing on the marginal distributions of FA levels and a chi-squared (χ2) test using the 
estimated metabotype frequencies and find that the LRT is most powerful across a wide variety of 
situations. We then apply our methodology to the previously analyzed case-control study of 767 ACS-
cases and their matched controls(14) to determine whether multiple populations of FA elongase and 
destaturases can be identified and if so whether the relative abundance of these populations differ between 
cases and controls. Numerous differences in cases and controls metabotype frequencies are identified and 
the resulting insights enhance biological interpretability. 
Methods:   
Summary of approach:    We first validated the proposed test using simulated data, then applied it to an 
established fatty acid dataset where conclusions regarding risk for ACS could be drawn.  In validating the 
novel statistical approach (LRT), two objectives were considered: 1) demonstrating that the test yields an 
accurate type I (α; false positive) error rate; and 2) that when an effect is present, the test finds the effect 
(1-β (power); true positive).  Since the proposed test more plausibly conforms to biological mechanisms 
than the current standard, our primary endpoint was to demonstrate power equivalent to current 
approaches. As a secondary endpoint, we sought to demonstrate that the test outperforms current 
approaches in some situations.   
In applying the test to real world data, we used a fatty acid dataset where prior knowledge of its 
usefulness existed (14).  Here, the LRT test was used to answer two questions: 1) do multiple components, 
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also contextually referred to as metabotypes, exist in the sampled populations; 2) is there a difference 
between the mixing proportions in the control and ACS populations; or more simply: does one 
metabotype appear to confer risk for ACS by virtue of greater prevalence among ACS subjects.  Although 
many factors might explain why there are multiple metabotypes in a sample population, consideration of 
how genetics-induced differences in enzymatic function might appear in a lipidomic analysis of large 
cohorts guided our development of this approach.  Thus we also utilized genetic models of inheritance 
(dominant, recessive and additive where appropriate to determine whether the observations of 
metabotypes conformed to it.  
Ethical Statements and compliance: This research was performed in accordance with the ethical principles 
for medical research involving human subjects outlined in the Declaration of Helsinki. The study was 
approved by the Institutional Review Board of Saint Luke’s Hospital and the Institutional Review Board 
of the University of Missouri-Kansas City School of Medicine.   
Subject Selection.  Patients diagnosed with an ACS were recruited as previously described. A total of 
1,661 patients were enrolled and samples obtained.  Control subjects having routine blood draws were 
recruited as described from the same location as >80% of the cases.   
Laboratory Methods: RBC-FA composition was measured as previously described(17) using the boron 
triflouride methylation method and followed by gas chromatography (GC) analysis using an Agilent 6890 
(Agilent Technologies, Palo Alto, CA) equipped with a capillary column (SP2560, 100m., Supelco, 
Bellefonte, PA).  
Activity Biomarkers:  We used product:precursor ratios in pathways of human fatty acid metabolism to 
obtain estimates of bioactivity (Supplemental Figure 1).  A summary of each activity biomarker is listed in 
supplementary figure 1b.  Since our intention was to develop an analytical approach combining both 
genetic and metabolomic considerations, we reference the activity estimates by the predominant human 
gene responsible for the activity however as noted, there could be other explanations for the presence of 
multiple components. 
Test validation via simulation:  To evaluate the performance of different statistical tests for case-control 
differences in FA levels, we conducted two main simulation studies: 1) data simulated from a two 
component mixture model; 2) data simulated from a three component mixture model.   
In the simulation analysis involving a two-component mixture model we simulated two normal 
distributions, with a one unit difference in means between the two components.  We considered standard 
deviations in the first group of either s1=0.25 or 0.50, and standard deviations in the second component 
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(s2) either the same, 50% larger or 100% larger than the first component. We simulated 800 cases and 800 
controls from the two component normal mixture distribution, where the mixing proportions (p1 and p2) 
may be the same (no association between genotype and disease) or different (association between 
genotype and disease) in the cases and controls. The proportion of controls in component 1 was simulated 
to follow either a dominant or recessive genetic mode of inheritance. In particular, we considered risk 
(minor) allele frequencies of f=5%, 10%, 25%, 33% and 50%. Under an assumption of Hardy-Weinberg 
Equilibrium, this yields the following proportions of controls in component 2 (p2,controls; Dominant: 9.75%, 
19%, 43.75%, 55.1% and 75%; Recessive: 0.25%, 1%, 6.25%, 10.9% and 25%, where these proportions 
are computed as p2,controls,dominant = f
2
+2f(1-f) and p2,controls,recessive= f
2
.  The proportion of cases in component 
1, p1,cases was set to either be the same, 90%, 75% or 50% the size of p1,controls, representing a risk allele 
with varying amounts of impact on disease risk. Thus, there were a total of 240 simulation settings (2 (s1) 
x 3 (s2) x 10 (p2,controls) x 4 (p2,cases) considering a two-component normal distribution. Five-hundred 
randomly generated sets of data were created for each simulation setting. Empirical type I error and power 
were both computed as the proportion of the 500 data sets for which the p-value was less than 0.05. 
We also simulated data from a three component normal mixture model. We considered the 
following settings. All simulation settings used a 1-unit difference between each of the three means of the 
components. The standard deviation for the first component was either 0.25 or 0.50, while the standard 
deviations of the remaining components were either the same, or different (50% larger in second, 100% 
larger in third). We simulated 800 cases and 800 controls. Similar to the two-component mixture 
simulation, we considered risk (minor) allele frequencies of f=5%, 10%, 25%, 33% and 50%. The size of 
the three components in the controls was again determined using Hardy-Weinberg equilibrium. Case 
proportions in components one, two and three were computed to represent an additive, increasing risk 
model. In particular, Xg1,(1-X)g1+Xg2, (1-X)g2+g3, are the three case component proportions respectively, 
where X=1, 0.9, 0.75 or 0.5, and g1, g2 and g3 represent the component proportions in the controls. Thus, 
there were a total of 80 simulation settings (2 (s1) x 2 (s2) x 5 (p2,controls) x 4 (p2,cases) using a three-
component normal distribution. 
Methods of analyzing metabotype data:  When analyzing simulated and real data, we used a variety of 
methods of analyzing fatty acid levels.  To aid in the understanding of these approaches we begin by 
introducing some notation. Let    represent a random variable indicating the observed fatty acid level 
when an individual is truly in the i
th
 metabotype. We assume that     (     ), where       indicate the 
mean and standard deviation of the normally distributed fatty acid levels within the i
th
 metabotype. 
Then,  ∑       
 
   , where   represents the observed distribution of fatty levels within the case 
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population, and      is the proportion of cases with the ith metabotype, where ∑     
 
      and k indicates 
the number of distinct metabotypes. Similarly,   ∑       
 
   . 
Standard methods of evaluating differences in   and   include the t-test, which uses   
 ̅  ̅
   
, where  ̅  ̅ 
are the sample means of the cases and controls, and     , is a function of the sample standard deviations 
(sx, sy) and sample sizes (nx, ny) in the case and control samples, respectively, and can be estimated using 
assumptions of equal or unequal variance. A common non-parametric alternative is the Mann-Whitney 
test, which first computes the ranks, rj, of the nx + ny combined sample of fatty acid levels, and then 
evaluates the difference between the average rank of the case and control samples ( ̅   ̅ ) and the expected 
average rank if the samples were from the same population. 
We consider two methods here which reflect the underlying assumption of observed samples 
which are mixtures of different metabotypes. The first method using metabotypes is a χ2 test of 
independence can be used on the resulting 2xk table of categorized individuals which occurs from cross-
classifying individuals by disease status and estimated metabotype. Metabotypes were estimated by using 
MClust (18) to fit a 2 or 3 component mixture distributions using an Expectation-Maximization algorithm. 
For a given mixture model, each individual can be assigned a vector of posterior probabilities 
corresponding to the individuals likelihood of belonging to each component of the mixture distribution 
(see details in the following section). An individual can then be classified to the “most likely” metabotype 
by using the maximum posterior probability.  The second method (19) does not require the use of 
maximum posterior probabilities to classify individuals into metabotypes. Instead, Kim et al. use a 
likelihood ratio test (LRT) to compare the full distribution of posterior metabotype probabilities between 
cases and controls. Two different versions of the LRT were considered: (1) one where the number of 
distinct metabotypes (k) was considered known a priori (LRTk); (2) one where the number of distinct 
metabotypes (k) was estimated from the data (LRTest). 
Statistical analysis of simulated data: Data was simulated as described earlier using R version 3.0.3. Each 
of the different methods of analyzing fatty acid data (see Methods of analyzing metabotype data) was then 
applied to the data yielding a p-value measuring the strength of evidence of a difference in the means, 
distributions, or mixing proportions of metabotypes between cases and controls, depending on the test 
used. Type I error rates and power were estimated by dividing the number of simulations yielding a p-
value less than 0.05 by the total number of simulations at that setting.  For the LRT test, a single 
component represents a case where no difference exists.  
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Statistical analysis of real data: We used a multi-step procedure to analyze the real fatty acid data. First, 
we used Mclust (18) to fit 1, 2 or 3 component mixtures of equal variance normal distributions to each of 
the 14 fatty acid ratios, for a total of three different models being estimated on each fatty acid ratio. The 
model yielding the largest Bayesian Information Criterion (BIC) was deemed the best fitting model for the 
FA. The guidelines of Raftery (20) were used to ensure the best fitting model was significantly better than 
other models, namely, that the improvement in BIC is at least 6 when comparing the best to second best 
fitting model. We also fit models after dropping the most extreme 0.5% of the FA values (top 0.25% and 
bottom 0.25%), since this class of model fitting techniques can be sensitive to extreme values (21). 
We then applied the LRT (see Methods of analyzing metabotype data for details) to each data 
using the estimated number of components. All other tests described above were also applied to the data.  
Odds ratios were estimated using a logistic regression model predicting case-control status by each 
individual’s metabotype posterior probability for a particular fatty acid. Recent related results have 
illustrated the near optimality (vs. LRT) of using posterior probabilities to predict case-control status in 
such models (22). Two sided tests at significance level 5% were used in all cases. Missing FA data was 
below 0.8% (range 0-0.8%) for all 9 of the FA ratios. 
Results:  
Two component simulations: The type I error rate (false positives) for the proposed LRT test was well 
controlled (Supplemental Table 1), and this was the case whether we affirmed prior knowledge of two 
metabotypes (LRT2) or if the number of metabotypes was unknown and the test was required to estimate 
the metabotype number (LRTest).  The type I error rate was comparable and well-controlled by all methods 
(equal and unequal variance t-tests, Mann-Whitney test, χ2 test, LRT2 and LRTest) across all simulation 
settings considered here.  In particular, in almost all cases, a 95% CI on the empirical type I error rate 
contains the nominal type I error rate of 5%.  Minor exceptions occurred when the sample size of one 
component was small, yielding slightly conservative or slightly liberal type I error rates for methods 
estimating metabotype proportions from the data (χ2 test, LRT2 and LRTest). 
In addition to control of type 1 errors, both LRT methods provided superior power in most 
scenarios.  Supplemental Table 2 illustrates the power of case-control association tests when there is a 
difference between component proportions in cases and controls.  Ninety-two of 180 simulation settings 
yielded power greater than 99% for all 6 methods considered here, meaning model selection is not 
particularly important in such contexts.  In 70 out of the remaining 88 settings, the LRT2 yields power 
equivalent to or better than the equal variance t-test, the unequal variance t-test, the Mann-Whitney test 
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and the χ2 test. On average, LRT2 provided an increase in power of 4 percentage points compared to both 
the equal and unequal variance t-tests (min=0, max 15 point increase), 12.5 percentage points more power 
than the Mann-Whitney test (min=0, max=44.4 point increase) and 3.9 percentage points more power than 
the χ2 test (min=0, max=15.4 percentage points).  In the 18 settings when the LRT2
 
was not the most 
powerful test, the equal and unequal variance t-tests were on average 0.7 percentage points better (min= -1 
point, max=2.4 points), the Mann-Whitney test was, on average, 2.6 points better (min= -0.8 points, 
max=8.8 points) and the chi-squared test was, on average, 8.2 points better (min=0, max=21.6 points). 
LRT2 tended to be best when the standard deviations were smaller and equal and when differences in the 
case-control proportions were smaller. 
In 59 out of the 88 settings LRTest yielded power equivalent to or better than the equal variance t-
test, the unequal variance t-test, the Mann-Whitney test and the χ2 test. On average across the 59 settings, 
LRTest provided 4 percentage points more power than both the equal and unequal variance t-tests (min=0, 
max=15 points), 13.9 points better than the Mann-Whitney test (min=0.2 points, max=44.4 points) and 4 
points better than the χ2 test (min=0, max=15.4 points).  In the remaining 29 settings the average amount 
that both t-tests were better than LRTest was 1.1 points (min= - 2.4 points, max=6.4 points), for Mann-
Whitney the average improvement was 2.2 points (min= - 1.8 points, max=8.6 points) and for the χ2 test 
the average improvement was 4 points (min= - 15.8 points, max=5.6 points). LRTest tended to be optimal 
in the same situations as LRT2. 
Figure 2 illustrates simulation setting where 90.25% of controls are in component 1 and 81.2% of 
cases are in component 1. The standard deviation is the same in both components and varies on the x-axis; 
the difference in component means is fixed at 1. The figure illustrates that the LRTest is more powerful 
than all other tests in this case.  
Three component simulations: The type I error rate for the χ2 test, the LRT3, and the LRTest was well 
controlled for settings with three components (Supplemental Table 3) as long as the sample size in each of 
the three components was reasonably large (at least three observations).  The t-tests and Mann-Whitney 
tests showed type I error control in all situations.  Twenty-one of 60 settings yielded power greater than 
99% for all six methods considered here, meaning model selection is not particularly important in such 
contexts.  In 11 of the remaining 39 settings the LRT3 is the most powerful, with average power gain vs 
the t-test of 0.3 points (min=0, max=1.6 points), vs. the Mann-Whitney test of 2.6 points (min=0, 
max=15.4 points) and vs. the χ2test of 46.4 points (min=0, max=100 points), however we note that the χ2 
test often suffers from small sample size issues in this simulation, yielding low power.  In 24 of the 39 
settings LRTest was the most powerful of all methods with an average improvement vs. the t-test of 1 point 
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(min=0, max=7 points), vs. Mann-Whitney 5.7 points (min=0, max=26.8 points) and 56.7 points vs. χ2 
(min=1.2 points, max=100 points).  In general, across the settings we investigated it was much harder to 
correctly identify the data as being produced from a three-component mixture model, than a two 
component mixture.  We note that in many cases the best model was a two component model because of 
the small number of individuals present in the third component. As sample size increases the performance 
of the three component mixture model and test improves (details not shown). In general, the LRT test 
performs better than other tests in similar ways to those described earlier. 
Case and control plasma fatty acids: The means and standard deviations overall, and within each of the 
case-control samples for each of the fourteen fatty acid ratios considered here are provided in 
Supplemental Table 5.  Correlation between fatty acid ratios are provided in Supplemental Table 6.  
Notably, correlations within closely related pathways are stronger than among distantly related ones.   
Metabotypes estimations: We defined metabotypes to be single components of each mixture, and each 
component could be comprised of case or control subjects.   We used MClust to fit 1, 2 and 3 component 
mixtures of normal distributions for each of the activity surrogates (i.e. fatty acid ratios).  Most fatty acids 
had a clear “best fitting model” that was robust to the potential presence of outliers.  Of the 14 activity 
biomarkers explored, eleven were clearly mixtures of two components.  One activity, ELVOL2, was 
ambiguously either not different or a mixture of three components (see Supplemental Tables 7a and 7b for 
details), and no further analysis was conducted.  
Case/control Metabotype differences: We next tested whether the proportion of metabotypes differed 
among cases and controls.  Table 1 gives the estimated means and standard deviations of each component 
for the 11 activity biomarkers for which a 2-component normal mixture model fit best.  Among enzymes 
acting on saturated and mono-unsaturated fatty acids, two differences were notable: D9D activity and 
ELOVL6 activity.  For D9D activity on 16- and 18-carbon fatty acids, two metabotypes were present: a 
more common low activity metabotype, and a metabotype with a higher mean activity.  While this high 
activity metabotype was less common,  the higher 18:1n9/18:0 ratio was more abundant in cases (14.8%) 
than controls (7.1%) (Pundajusted<0.0001).  Adjusting for other fatty acids in the pathway nullified the 
difference however a reduced risk, Odds Ratio (OR)=0.3 [0.2, 0.6; Padjusted<0.0001], persisted for subjects 
with higher 18:1n9/18:0 based activity than on the 16:1n7/16:0-based activity.  Two metabotypes were 
also observed among ELOVL6 populations.  While only 40% of control subjects had the lower activity 
metabotype, nearly 50% of cases did (P<0.0001) suggesting lower elongation activity is associated with a 
higher risk. 
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Similarly, key difference among cases and controls were observed among biomarkers of enzymes 
acting on polyunsaturated fatty acids.  Three differences were noted: ELOVL5 activity on omega-6 fatty 
acids, Sprecher pathway chain shortening activity, and FADS1 activity; the lattermost only apparent after 
adjustment.  For ELVOL5, only 7% of controls had the high activity metabotype compared to 20% of 
cases (Padjusted<0.0001), indicating metabotypes having increased elongation of gLA to dgLA can confer 
risk.  The production of 22-carbon fatty acids (n6-DPA and DHA) is a multi-step process sometimes 
termed Sprecher-pathway chain shortening (SCS).  Subjects with high SCS activity on omega-3 fatty 
acids represented 10% of the controls, however they represented only 4.5% of the cases.  Adjustment for 
other fatty acids ablated this effect, however the effect persisted when the relative SCS activity on omega-
3 to omega-6 fatty acids was measured, and subjects with the metabotype associated with relatively more 
omega-3 (DHA) production had lower risk for ACS, OR= 0.3 [0.1, 0.5].  After adjustment, a third 
difference emerged for FADS1, where efficient conversion of dgLA to AA was more prevalent among 
cases than controls. 
The different proportions of metabotypes in cases and controls allow for calculation of odds ratios.  
Since single component populations allows for only a continuously increasing or decreasing odds ratio 
across sample values, a particular advantage of conceptualizing multiple components is the possibility of 
identify more biologically intuitive odds patterns.  Figure 3 plots the estimated odds from the two-
component mixture model of D9D activity when expressed as the OA/SA ratio and the odds ratio is 
frequency of the cases and controls at each  activity, the observed odds, and the odds obtained from a 
means model. As can be observed in the figure, the 2-component mixture model appears to fit the 
observed data better than the means model, confirming our intuition. 
Discussion: 
Identifying disease risk factors and predicting risk have become key elements in modern health 
care and effective intervention policy.  The prevalent approach to risk identification is through means 
testing of measured metabolic and life style factors between populations of cases and controls.  However, 
an inherent weakness to means testing is the assumption that collected samples represent a selection from 
a single population, and the impact of this assumption is most apparent with large heterogeneous sample 
sets.  We demonstrate a test that robustly detects populations with multiple components (aka, multi-modal 
distributions).  Using the test, our study population was empirically found to be multi-modal and thus 
violates this assumption.  Both genetic and environmental factors can provide sources of variance 
responsible for this violation.  For instance some gene polymorphisms can result in functional changes, 
direct or epistatic, that would impart a discontinuous, digital shift in measures of activity.  Alternatively, 
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metabolic variance due to environmental factors, including diet and lifestyle, would impart continuous 
variance.  Thus, a unified explanation of environmental factors and Mendelian genetics implies digital 
shifts overlain on continuous variation, or multi-modal distributions.  Based on these facts, we 
hypothesize that sample sets with multiple metabotype components, as opposed to a single component, 
should be expected.  Here we term these components metabotypes.  Metabotypes are commonly conceived 
in metabolomic terms, representing broad fingerprint-like patterns of metabolites that act as phenotypes 
and so inform diagnostic or prognostic studies (23).  Here, we apply the concept of a metabolic phenotype 
more narrowly to specific metabolic activities and overlay the biomarker concept with the prevailing 
genetic theory.  While studies have merged genetic and metabolic data for risk assessment (24), here we 
incorporate prior knowledge of diet-gene interaction to develop a likelihood ratio test that more faithfully 
reflects the biology of both. 
Using simulated sample sets, the LRT test was found to not only detect mixed populations, but in 
doing so provided great power to discriminate true means in nearly every scenario tested.    In addition, 
the LRTest gives added biological insight.  By accounting for the expected variance conferred by 
functional genetic differences as the component means themselves, from that  conferred by nutritional 
status and lifestyle as the variance off means, we give insight into how these axes of risk interact.  For 
instance, because a lifestyle confers risk by elevating a biomarker, it is not clear or necessary that genes 
which elevate the same biomarker would also confer risk.  In cases where genetic risk operates in the 
opposite direction as nutritional/lifestyle the simpler analyses would obfuscate biomarker interpretation, 
which would be especially revealed by the LRTest analysis.  The LRTest also effectively identifies 
important functional phenotypes in lieu of null variants, and so could be used to effectively identify the 
subset of genes whose polymorphism actually results in functional alterations.  Since SNP analyses do not 
measure functional alterations, this approach could provide guidance to such approaches.  Here, we have 
identified distinct fatty acid metabolism metabotypes which are associated with increased risk of ACS.  
By implication, we have also identified optimal activities (Figure 3), in contrast to means testing 
techniques which do not allow for local optima as they can only provide monotonic changes. 
Metabotypes with greater desaturation activity on stearic acid were at increased risk for ACS 
compared to activity on palmitic acid, and effect that persists after adjusting for other correlated activities.  
At least two genes encode enzymes with D9D activity in humans (25), and increasing activity is 
associated with increase adiposity (26).  Prior tracer work confirms higher desaturase activity on SA (27), 
and this biomarker is a predictor of risk for cardiovascular disease mortality (28).  By contrast there is no 
direct evidence for a role of ELOVL6 in heart disease, however by elongating the SCD precursor PA to 
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SA, high ELOVL6 activity is thought to contribute to palmitate-induced lipotoxicity (29).  ELVOL6 are 
related to co-morbidities of heart disease including gene polymorphisms in insulin resistance (30, 31) and 
increased activity in hepatic steatosis (32).  We observed that metabotypes with increased ELOVL6 
activity is protective.  However, since our analysis focuses on the effect of belonging to a metabotype, and 
not deviating from a metabotype mean, it is not necessary to conclude these observations are conflicting. 
We did not find evidence for FADS2 activity in risk, however efficient metabotypes of ELOVL5 
and FADS1 were associated with increased risk, the latter only after adjustment.  ELOVL5 
polymorphisms were not associated with either risk for myocardial infarction but were associated with 
risk intermediates such as LDL-cholesterol (33).  Such failure to replicate highlights the potential for 
methodologies that combine approaches to increase analytical power.  The delta5-desaturase activity 
mediates the conversion of DGLA (20:3n6) to AA (20:4n6) as well as eicosatetraenoic acid (20:4n3) to 
EPA (20:5n3) and has been associated with numerous pathologies.  Based on biomarkers from cholesteryl 
ester pools, Lu et al observed a polymorphism of high delta 5-desaturase activity (rs174547) is associated 
with reduced risk for coronary heart disease (34), and other cases are reported where high δ5-desaturase 
activity is associated with reduced risk (35).  Such findings identify activities associated with risk, 
however our model suggests at least part of the risk results from metabotypes with differing efficiencies, 
providing insight into possible gene/lifestyle interaction.   
We have approached our analysis based on the assumption that metabotypes result from genetic 
polymorphisms however other factors, environmental or unknown, could also establish them.  In the latter 
case, environment is common and correlation of metabotypes is more likely, however in the former case, 
dependence is unnecessary and less likely.  Thus, demonstrating independence is an inference (albeit 
weak) supporting a genetic basis.  We make two findings of independence: lack of correlation between 
fatty acids of different pathways and an additive effect of metabotype membership.  Notably, the strongest 
correlation is observed among closely related activities (outlined in bold), less strong as activities become 
more distant.  Further metabotype information alone, independent of variance off the means predicts a 
large portion of cases, consistent with independence and direct a role for metabotypes in ACS risk 
(Supplemental Figure 2). 
Implications: Recent reports have highlighted the difficulties associated with residual risk, including one 
report from this same study where SNP analyses showed no genome-wide associations with myocardial 
infarction (13).  Our test not only provides greater explanation of the data, it is formed by combining basic 
principles of genetics and environmental factors and so provides straightforward interpretation.  Since it 
predicts populations with multi-modal properties, it has the added benefit of not being constrained to the 
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unrealistic prediction that risk is monotonic with respect to activity: risk can either plateau or reach local 
maxima and minima.  While the latter usually requires at least three components (not found here), we 
identified plateaued risk (Figure 3) where decreasing D9D activity did not monotonically decrease risk.  
Identifying such locales could guide interventions by providing metabolically ideal targets, or in the 
example case, a threshold above which measures to decrease activity could be beneficial. 
Limitations: We have interpreted most of our results by extrapolating to the expected genetics underlying 
the metabotypes; however, factors other than genetics may be responsible for their presence.  We have 
additionally inferred that the biomarkers reflect the apparent functional enzyme activities.  While 
common, this presupposes that changes in precursor rate of appearance and product rate of clearance are 
not responsible for the changes.  Thus, while we have robustly detected metabotypes, we cannot make 
strong inferences to mechanism.  It is hoped we can validate their application to risk estimation in future 
studies.  Our method is only likely to detect metabotypes that are widely separated and would be restricted 
to large datasets.  If metabotypes are truly attributable to genetic polymorphisms, the additive genetic 
model would predict three distinct metabotypes, however in most cases we detect only two.  This is likely 
due to the expected small abundance of recessive metabotypes, and would need to be confirmed in 
datasets where the recessive phenotype is more abundant. 
Conclusions: We have verified a novel approach to understand how fatty acids and other continuous 
metabolomic datasets could be evaluated for relationships to risk.  We further validated this test, in the 
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Table 1. Evaluating relationships between FA ratio and case-control status 
FA Ratio Best model Model Details  

















Case Control   
Short-chain desaturase       
D9D C16 2 Metabotype 





(0.4, 2.3) M2: 0.12 (0.02) 10.0 8.5 
D9D C18 2 Metabotype 







(0.8, 2.7) M2: 1.96 (0.25) 14.8 7.1 
D9D 16:18 2 Metabotype 





(0.2, 0.6)*** M2: 0.08 (0.01) 4.5 8.8 
ELOVL6 2 Metabotype 

















(0.5, 3.2) M2: 0.16 (0.02) 7.5 7.6 
Arachidonate synthesis pathway 
FADS2 2 Metabotype 





(0.5, 1.6) M2: 0.05 (0.01) 4.5 6.4 
ELOVL5 2 Metabotype 







(3.7, 8.9)*** M2: 6.4 (1.0) 19.7 7.4 
FADS1 2 Metabotype 





(1.1, 2.8)*** M2: 12.3 (2.0) 10.3 8.0 
Docosanoid synthesis pathway      
SCS n6 2 Metabotype 





(0.9, 2.6) M2: 0.22 (0.04) 7.8 5.6 
SCS n3 2 Metabotype 







(0.4, 1.5) M2: 3.2 (0.5) 4.5 10.3 
SCS n3:n6 2 Metabotype 
M1: 7.9 (2.5) 












*p<0.05, **p<0.01, ***p<0.001 
a
ORs are interpreted as the increase in the likelihood of being a case given you are in metabotype 2. 
b





0 1 2 3
A










S o l i d  B l a c k
G r e y  D a s h e d




































F i g u r e  1 :  M e a n  d i f f e r e n c e s  a r e  n o t  a p p l i c a b l e  i n  s a m p l e s  w i t h  m u l t i p l e
p o p u l a t i o n s .   P a n e l  A  i l l u s t r a t e s  t w o  p o p u l a t i o n s  w i t h  n o r m a l  d i s t r i b u t i o n  a n d
e q u a l  v a r i a n c e  ( S D  =  0 . 2 8 ) .   T h e  s o l i d  b l a c k  p o p u l a t i o n  i s  c e n t e r e d  a t  1 . 2 3  a n d
t h e  d a s h e d  g r e y  p o p u l a t i o n  i s  c e n t e r e d  a t  1 . 3 0 .   I n  t h i s  c o n t e x t  c o m p a r i s o n  o f
m e a n s  a r e  m a d e  u s i n g  F - d i s t r i b u t i o n s  t o  d e t e r m i n e  t h e  p r o b a b i l i t y  t h a t  t h e y  a r e
t h e  s a m e .   B i n n e d  d a t a  c o r r e s p o n d i n g  t o  a  b i o m a r k e r  f o r  d e s a t u r a t i o n  o f  s t e a r i c
a c i d  t o  o l e i c  a c i d ,  o r  9 D  a c t i v i t y ,  a r e  s h o w n  b y  d a t a  p o i n t s ,  a n d  s k e w e d  f r o m
n o r m a l i t y . I n  p a n e l  B ,  t h e  d i s t r i b u t i o n  o f  t h e  c o n t r o l  ( p a n e l  A ,  s o l i d  b l a c k )
d a t a  i s  f i t  t o  t w o  g a u s s i a n  d i s t r i b u t i o n s  ( b o l d  b l a c k  l i n e ) .   T w o  p h e n o t y p e s  o f
 9 D a c t i v i t y  e x i s t  h e r e ,  t h e  f i r s t ,  r e p r e s e n t i n g  i n e f f i c i e n t  6 D  a c t i v i t y  a t  1 . 1 7 
0 . 2 5  a n d  t h e  s e c o n d  r e p r e s e n t i n g  e f f i c i e n t  a c t i v i t y  a t  1 . 9 6   0 . 2 5 .   U s i n g
c o m p o n e n t  m i x t u r e  m o d e l i n g ,  t h e  d i s t r i b u t i o n s  o f  e a c h  m e t a b o t y p e ,  o r
m e t a b o l i c  p h e n o t y p e ,  h a v e  b e e n  d e c o n v o l u t e d  f r o m  t h e  p a r e n t  d i s t r i b u t i o n . I n
p a n e l  C ,  t h e  d e c o n v o l u t i o n  c a n  b e  u s e d  t o  t e s t  w h e t h e r  t h e  a p p a r e n t  a b u n d a n c e
o f  t h e  e f f i c i e n t  6 D  p h e n o p t y p e  o c c u r s  m o r e  f r e q u e n t l y  a m o n g  t h e  c a s e s  ( a s  i t
a p p a r e n t l y  d o e s )  a n d  w h e t h e r  t h e  l e s s  e f f i c i e n t  p h e n o t y p e  o c c u r s  w i t h  g r e a t e r
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Figure 2: The power of LRT is superior, especially with increased variance.  Results for simulations for 
power to detect differences where 90.25% of controls are in component 1 and 81.2% of cases are in 





Figure 3: Observed odds more closely resemble estimates of mixture models.  Odds 
estimates for the mixture model are computed by finding the ratio of the estimated density 
functions for the metabotypes, for the logistic model (predicting case-control status by FA 
level directly) they are found directly from the model. Observed odds ratios were estimated 




Figure 3. Estimated and predicted odds of being a case at varying levels of D9D-C18 
1 . 0 1 . 5 2 . 0
C 1 8  D 9 D  a c t i v i t y
















L o g i s i t c
M i x t u r e





















in grp 1  
Type I error rate of different statistical analysis methods 
Percent of 500 
simulations yielding 
















0.25 0.25 0.25 0.25 0.064 0.064 0.064 0.048 0.06 0.06 0 1 0 
0.25 0.375 0.25 0.25 0.036 0.036 0.032 0.036 0.052 0.048 0 0.338 0.662 
0.25 0.5 0.25 0.25 0.038 0.038 0.042 0.036 0.038 0.04 0 0.018 0.982 
0.25 0.25 0.449 0.449 0.056 0.056 0.06 0.05 0.052 0.052 0 1 0 
0.25 0.375 0.449 0.449 0.056 0.056 0.062 0.054 0.072 0.068 0 0.056 0.944 
0.25 0.5 0.449 0.449 0.042 0.042 0.042 0.038 0.05 0.04 0 0.148 0.852 
0.25 0.25 0.5625 0.5625 0.05 0.05 0.042 0.048 0.058 0.058 0 1 0 
0.25 0.375 0.5625 0.5625 0.036 0.036 0.036 0.046 0.054 0.054 0 0.962 0.038 
0.25 0.5 0.5625 0.5625 0.058 0.058 0.058 0.066 0.064 0.064 0 1 0 
0.25 0.25 0.81 0.81 0.062 0.062 0.058 0.048 0.056 0.056 0 0.998 0.002 
0.25 0.375 0.81 0.81 0.056 0.056 0.068 0.048 0.056 0.056 0 1 0 
0.25 0.5 0.81 0.81 0.034 0.032 0.034 0.026 0.028 0.028 0 1 0 
0.25 0.25 0.9025 0.9025 0.074 0.074 0.062 0.06 0.066 0.066 0 0.998 0.002 
0.25 0.375 0.9025 0.9025 0.038 0.038 0.046 0.04 0.05 0.05 0 1 0 
0.25 0.5 0.9025 0.9025 0.056 0.056 0.05 0.04 0.056 0.056 0 1 0 
0.25 0.25 0.75 0.75 0.046 0.046 0.052 0.034 0.032 0.032 0 1 0 
0.25 0.375 0.75 0.75 0.04 0.04 0.04 0.04 0.06 0.06 0 1 0 
0.25 0.5 0.75 0.75 0.046 0.046 0.048 0.032 0.046 0.046 0 1 0 
0.25 0.25 0.891 0.891 0.05 0.05 0.054 0.06 0.064 0.064 0 0.998 0.002 
0.25 0.375 0.891 0.891 0.054 0.054 0.054 0.042 0.056 0.056 0 1 0 
0.25 0.5 0.891 0.891 0.066 0.066 0.072 0.032 0.046 0.046 0 1 0 
0.25 0.25 0.9375 0.9375 0.038 0.038 0.032 0.034 0.05 0.05 0 1 0 
0.25 0.375 0.9375 0.9375 0.05 0.05 0.04 0.04 0.048 0.048 0 1 0 
0.25 0.5 0.9375 0.9375 0.054 0.054 0.052 0.032 0.032 0.032 0 1 0 
0.25 0.25 0.99 0.99 0.044 0.044 0.042 0.028 0.048 0.038 0.02 0.794 0.186 
21 
0.25 0.375 0.99 0.99 0.038 0.038 0.036 0.012 0.048 0.038 0.012 0.594 0.394 
0.25 0.5 0.99 0.99 0.052 0.052 0.038 0.038 0.06 0.068 0.012 0.408 0.58 
0.25 0.25 0.9975 0.9975 0.032 0.032 0.036 0.038 0.058 --
a
 0.682 0.172 0.146 
0.25 0.375 0.9975 0.9975 0.058 0.058 0.056 0.036 0.092 --
a
 0.578 0.176 0.246 
0.25 0.5 0.9975 0.9975 0.062 0.062 0.058 0.034 0.064 --
a
 0.49 0.132 0.378 
0.5 0.5 0.25 0.25 0.036 0.036 0.04 0.048 0.04 0.04 0 1 0 
0.5 0.75 0.25 0.25 0.034 0.034 0.04 0.038 0.042 --
a
 0.24 0.746 0.014 
0.5 1 0.25 0.25 0.048 0.048 0.044 0.04 0.056 0.056 0 0.998 0.002 
0.5 0.5 0.449 0.449 0.062 0.062 0.058 0.052 0.052 0.05 0.014 0.984 0.002 
0.5 0.75 0.449 0.449 0.066 0.066 0.052 0.058 0.058 0.058 0 0.984 0.016 
0.5 1 0.449 0.449 0.054 0.054 0.054 0.04 0.046 0.046 0 1 0 
0.5 0.5 0.5625 0.5625 0.068 0.068 0.066 0.062 0.08 0.08 0.016 0.984 0 
0.5 0.75 0.5625 0.5625 0.042 0.042 0.044 0.038 0.052 0.052 0 1 0 
0.5 1 0.5625 0.5625 0.044 0.044 0.042 0.048 0.05 0.05 0 1 0 
0.5 0.5 0.81 0.81 0.058 0.058 0.062 0.04 0.052 0.052 0.002 0.998 0 
0.5 0.75 0.81 0.81 0.04 0.04 0.058 0.032 0.03 0.03 0 1 0 
0.5 1 0.81 0.81 0.048 0.048 0.052 0.042 0.056 0.056 0 1 0 
0.5 0.5 0.9025 0.9025 0.044 0.044 0.036 0.034 0.048 0.048 0.012 0.986 0.002 
0.5 0.75 0.9025 0.9025 0.046 0.046 0.058 0.024 0.04 0.04 0 1 0 
0.5 1 0.9025 0.9025 0.048 0.048 0.046 0.036 0.044 0.044 0 1 0 
0.5 0.5 0.75 0.75 0.034 0.034 0.038 0.028 0.028 0.028 0 1 0 
0.5 0.75 0.75 0.75 0.048 0.048 0.042 0.038 0.052 0.052 0 1 0 
0.5 1 0.75 0.75 0.058 0.058 0.066 0.032 0.046 0.046 0 1 0 
0.5 0.5 0.891 0.891 0.05 0.05 0.06 0.028 0.04 0.038 0.01 0.99 0 
0.5 0.75 0.891 0.891 0.054 0.054 0.044 0.04 0.048 0.048 0 1 0 
0.5 1 0.891 0.891 0.052 0.052 0.056 0.044 0.068 0.068 0 1 0 
0.5 0.5 0.9375 0.9375 0.042 0.042 0.034 0.042 0.038 --
a
 0.162 0.83 0.008 
0.5 0.75 0.9375 0.9375 0.046 0.046 0.042 0.038 0.046 0.048 0 0.976 0.024 
0.5 1 0.9375 0.9375 0.06 0.06 0.062 0.05 0.066 0.07 0 0.964 0.036 
0.5 0.5 0.99 0.99 0.05 0.05 0.056 0.06 0.076 --
a
 0.994 0.004 0.002 
0.5 0.75 0.99 0.99 0.06 0.06 0.056 0.046 0.054 --
a
 0.858 0.074 0.068 
0.5 1 0.99 0.99 0.048 0.048 0.052 0.058 0.07 --
a
 0.548 0.086 0.366 
0.5 0.5 0.9975 0.9975 0.046 0.046 0.048 0.034 0.072 --
a
 0.998 0.002 0 
22 
0.5 0.75 0.9975 0.9975 0.038 0.038 0.044 0.05 0.056 --
a
 0.996 0.002 0.002 
0.5 1 0.9975 0.9975 0.044 0.044 0.044 0.044 0.056 --
a
 0.946 0.016 0.038 
Bolded entries indicate type I error rates where the corresponding 95% CI does not include 5%, indicating empirical inflation of the nominal 
5% type I error rate 
a
















in grp 1  
Power of different statistical analysis methods 
Percent of 500 
simulations yielding 
















0.25 0.25 0.225 0.25 0.156 0.156 0.142 0.168 0.19 0.19 0 1 0 
0.25 0.25 0.1875 0.25 0.756 0.756 0.59 0.802 0.824 0.824 0 1 0 
0.25 0.375 0.225 0.25 0.116 0.116 0.122 0.154 0.166 0.14 0 0.37 0.63 
0.25 0.375 0.1875 0.25 0.64 0.64 0.56 0.668 0.728 0.69 0 0.438 0.562 
0.25 0.375 0.125 0.25 0.996 0.996 0.982 1 1 1 0 0.596 0.404 
0.25 0.5 0.225 0.25 0.12 0.12 0.116 0.086 0.108 0.1 0 0.024 0.976 
0.25 0.5 0.1875 0.25 0.514 0.514 0.508 0.43 0.55 0.506 0 0.064 0.936 
0.25 0.5 0.125 0.25 0.98 0.98 0.978 0.968 0.986 0.986 0 0.154 0.846 
0.25 0.25 0.4041 0.449 0.35 0.35 0.326 0.364 0.39 0.39 0 1 0 
0.25 0.25 0.33675 0.449 0.986 0.986 0.976 0.992 0.996 0.996 0 0.998 0.002 
0.25 0.375 0.4041 0.449 0.31 0.31 0.294 0.302 0.302 0.246 0 0.064 0.936 
0.25 0.375 0.33675 0.449 0.968 0.968 0.964 0.97 0.982 0.968 0 0.092 0.908 
0.25 0.5 0.4041 0.449 0.314 0.314 0.336 0.236 0.318 0.266 0 0.018 0.982 
0.25 0.5 0.33675 0.449 0.93 0.93 0.94 0.892 0.924 0.924 0 0 1 
0.25 0.25 0.50625 0.5625 0.506 0.506 0.476 0.534 0.582 0.582 0 1 0 
0.25 0.375 0.50625 0.5625 0.444 0.444 0.442 0.47 0.52 0.476 0 0.7 0.3 
0.25 0.5 0.50625 0.5625 0.41 0.41 0.406 0.372 0.418 0.418 0 1 0 
0.25 0.5 0.421875 0.5625 0.992 0.992 0.992 0.984 0.994 0.994 0 0.888 0.112 
0.25 0.25 0.729 0.81 0.908 0.908 0.794 0.958 0.968 0.968 0 0.998 0.002 
0.25 0.375 0.729 0.81 0.884 0.884 0.766 0.896 0.904 0.904 0 1 0 
0.25 0.5 0.729 0.81 0.868 0.868 0.754 0.854 0.898 0.898 0 1 0 
0.25 0.25 0.81225 0.9025 0.98 0.98 0.842 0.992 0.994 0.994 0 1 0 
0.25 0.375 0.81225 0.9025 0.982 0.982 0.858 0.992 0.998 0.998 0 1 0 
0.25 0.5 0.81225 0.9025 0.974 0.974 0.83 0.982 0.984 0.984 0 1 0 
0.25 0.25 0.675 0.75 0.84 0.84 0.778 0.87 0.882 0.882 0 1 0 
0.25 0.375 0.675 0.75 0.8 0.8 0.704 0.794 0.85 0.85 0 1 0 
24 
0.25 0.5 0.675 0.75 0.75 0.75 0.684 0.722 0.78 0.78 0 1 0 
0.25 0.25 0.8019 0.891 0.98 0.98 0.88 0.996 0.996 0.996 0 1 0 
0.25 0.375 0.8019 0.891 0.97 0.97 0.842 0.992 0.996 0.996 0 1 0 
0.25 0.5 0.8019 0.891 0.982 0.982 0.82 0.98 0.99 0.99 0 1 0 
0.25 0.25 0.84375 0.9375 0.998 0.998 0.908 1 1 1 0 1 0 
0.25 0.375 0.84375 0.9375 0.994 0.994 0.878 1 1 1 0 1 0 
0.25 0.5 0.84375 0.9375 0.99 0.99 0.854 0.996 0.998 0.998 0 1 0 
0.25 0.25 0.891 0.99 1 1 0.932 1 1 1 0 1 0 
0.25 0.375 0.891 0.99 1 1 0.91 1 1 1 0 1 0 
0.25 0.5 0.891 0.99 1 1 0.894 1 1 1 0 1 0 
0.25 0.25 0.89775 0.9975 1 1 0.938 1 1 1 0 1 0 
0.25 0.375 0.89775 0.9975 1 1 0.93 1 1 1 0 1 0 
0.25 0.5 0.89775 0.9975 1 1 0.886 1 1 1 0 1 0 
0.5 0.5 0.225 0.25 0.112 0.112 0.102 0.098 0.126 0.126 0 1 0 
0.5 0.5 0.1875 0.25 0.478 0.478 0.442 0.45 0.558 0.558 0.002 0.998 0 
0.5 0.5 0.125 0.25 0.978 0.978 0.948 0.978 0.994 0.994 0 1 0 
0.5 0.75 0.225 0.25 0.084 0.084 0.08 0.072 0.072 --
a
 0.344 0.642 0.014 
0.5 0.75 0.1875 0.25 0.358 0.358 0.378 0.246 0.354 --
a
 0.452 0.542 0.006 
0.5 0.75 0.125 0.25 0.864 0.864 0.886 0.678 0.84 --
a
 0.708 0.286 0.006 
0.5 1 0.225 0.25 0.086 0.086 0.09 0.064 0.08 0.08 0.002 0.986 0.012 
0.5 1 0.1875 0.25 0.232 0.232 0.27 0.156 0.22 0.214 0.018 0.978 0.004 
0.5 1 0.125 0.25 0.73 0.73 0.804 0.5 0.716 --
a
 0.074 0.918 0.008 
0.5 0.5 0.4041 0.449 0.23 0.23 0.248 0.21 0.262 0.26 0.008 0.992 0 
0.5 0.5 0.33675 0.449 0.894 0.894 0.914 0.876 0.93 0.926 0.006 0.994 0 
0.5 0.5 0.2245 0.449 1 1 1 1 1 0.988 0.012 0.988 0 
0.5 0.75 0.4041 0.449 0.174 0.174 0.186 0.13 0.194 0.196 0 0.978 0.022 
0.5 0.75 0.33675 0.449 0.798 0.798 0.83 0.636 0.794 0.794 0 0.986 0.014 
0.5 0.75 0.2245 0.449 1 1 1 0.99 1 0.994 0.006 0.958 0.036 
0.5 1 0.4041 0.449 0.168 0.168 0.164 0.108 0.156 0.156 0 1 0 
0.5 1 0.33675 0.449 0.63 0.63 0.698 0.458 0.612 0.612 0 1 0 
0.5 1 0.2245 0.449 0.99 0.99 0.998 0.948 0.994 0.994 0 1 0 
0.5 0.5 0.50625 0.5625 0.386 0.386 0.408 0.342 0.426 0.424 0.024 0.976 0 
0.5 0.5 0.421875 0.5625 0.97 0.97 0.98 0.96 0.986 0.962 0.024 0.976 0 
25 
0.5 0.5 0.28125 0.5625 1 1 1 1 1 0.982 0.018 0.982 0 
0.5 0.75 0.50625 0.5625 0.312 0.312 0.338 0.242 0.32 0.32 0 1 0 
0.5 0.75 0.421875 0.5625 0.95 0.95 0.96 0.842 0.936 0.936 0 0.99 0.01 
0.5 1 0.50625 0.5625 0.22 0.22 0.24 0.164 0.23 0.23 0 1 0 
0.5 1 0.421875 0.5625 0.866 0.866 0.88 0.728 0.856 0.856 0 1 0 
0.5 0.5 0.729 0.81 0.684 0.684 0.652 0.696 0.774 0.774 0 1 0 
0.5 0.5 0.405 0.81 1 1 1 1 1 0.984 0.016 0.984 0 
0.5 0.75 0.729 0.81 0.59 0.59 0.512 0.496 0.65 0.65 0 1 0 
0.5 1 0.729 0.81 0.538 0.538 0.388 0.454 0.574 0.574 0 1 0 
0.5 0.5 0.81225 0.9025 0.86 0.86 0.764 0.87 0.94 0.94 0 1 0 
0.5 0.75 0.81225 0.9025 0.806 0.806 0.654 0.788 0.906 0.906 0 1 0 
0.5 1 0.81225 0.9025 0.728 0.728 0.47 0.782 0.878 0.878 0 1 0 
0.5 0.5 0.675 0.75 0.62 0.62 0.622 0.602 0.686 0.684 0.004 0.996 0 
0.5 0.5 0.375 0.75 1 1 1 1 1 --
a
 0.03 0.97 0 
0.5 0.75 0.675 0.75 0.546 0.546 0.482 0.438 0.558 0.558 0 1 0 
0.5 1 0.675 0.75 0.486 0.486 0.386 0.41 0.526 0.526 0 1 0 
0.5 1 0.5625 0.75 0.99 0.99 0.984 0.964 0.992 0.992 0 1 0 
0.5 0.5 0.8019 0.891 0.808 0.808 0.708 0.826 0.916 0.914 0.002 0.998 0 
0.5 0.75 0.8019 0.891 0.75 0.75 0.606 0.714 0.836 0.836 0 1 0 
0.5 1 0.8019 0.891 0.704 0.704 0.474 0.736 0.842 0.842 0 1 0 
0.5 0.5 0.84375 0.9375 0.896 0.896 0.76 0.918 0.976 0.964 0.014 0.986 0 
0.5 0.75 0.84375 0.9375 0.846 0.846 0.646 0.854 0.946 0.946 0 1 0 
0.5 1 0.84375 0.9375 0.832 0.832 0.548 0.874 0.942 0.942 0 1 0 
0.5 0.5 0.891 0.99 0.946 0.946 0.814 0.98 1 --
a
 0.194 0.804 0.002 
0.5 0.75 0.891 0.99 0.932 0.932 0.718 0.988 0.998 0.998 0 0.976 0.024 
0.5 1 0.891 0.99 0.894 0.894 0.556 0.986 1 0.994 0 0.944 0.056 
0.5 0.5 0.89775 0.9975 0.95 0.95 0.838 0.97 1 --
a
 0.3 0.69 0.01 
0.5 0.75 0.89775 0.9975 0.942 0.942 0.698 0.978 1 0.994 0.006 0.922 0.072 
0.5 1 0.89775 0.9975 0.928 0.928 0.556 0.978 1 1 0 0.87 0.13 
a
 The best fitting model was often a 1 component model in these cases, making the LRTest unusable to test for a difference. 
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Type I error of different statistical analysis methods 
Percent of 500 
simulations yielding 
















0.5 0.5 0.5 0.25 0.066 0.066 0.066 0.06 0.06 0.076 0 0.85 0.15 
0.5 0.5 0.5 0.33 0.038 0.038 0.04 0.04 0.05 0.04 0.014 0.662 0.324 
0.5 0.5 0.5 0.5 0.048 0.048 0.044 0.04 0.064 --
a
 0.372 0.436 0.192 
0.5 0.75 1 0.05 0.046 0.046 0.052 0.046 0.07 0.046 0 0.998 0.002 
0.5 0.75 1 0.1 0.06 0.06 0.056 0.046 0.116 0.068 0 1 0 
0.5 0.5 0.5 0.05 0.04 0.04 0.046 0.046 0.07 0.056 0.006 0.994 0 
0.5 0.5 0.5 0.1 0.06 0.06 0.056 0.056 0.082 0.052 0 1 0 
0.5 0.75 1 0.25 0.06 0.06 0.06 0.048 0.058 0.066 0 1 0 
0.5 0.75 1 0.33 0.068 0.068 0.058 0.054 0.07 0.05 0 1 0 
0.5 0.75 1 0.5 0.046 0.046 0.052 0.056 0.07 0.056 0 0.54 0.46 
0.25 0.375 0.5 0.25 0.042 0.042 0.048 0.026 0.038 0.044 0 1 0 
0.25 0.375 0.5 0.33 0.042 0.042 0.042 0.048 0.05 0.054 0 0.124 0.876 
0.25 0.375 0.5 0.5 0.052 0.052 0.052 0.044 0.048 0.048 0 0 1 
0.25 0.25 0.25 0.25 0.032 0.032 0.042 0 0.05 0.052 0 0.996 0.004 
0.25 0.25 0.25 0.33 0.046 0.046 0.044 0.048 0.044 0.044 0 0 1 
0.25 0.25 0.25 0.5 0.054 0.054 0.056 0.054 0.062 0.062 0 0 1 
0.25 0.25 0.25 0.05 0.036 0.036 0.046 0.03 0.068 0.044 0 1 0 
0.25 0.25 0.25 0.1 0.036 0.036 0.038 0 0.086 0.058 0 1 0 
0.25 0.375 0.5 0.05 0.08 0.08 0.082 0.01 0.15 0.068 0 1 0 
0.25 0.375 0.5 0.1 0.05 0.05 0.046 0 0.08 0.056 0 1 0 
a
 The best fitting model was often a 1 component model in these cases, making the LRTest unusable to test for a difference. 
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Supplemental Table 4. Power for 3-component mixtures 
 
 Type I error of different statistical analysis methods 
Percent of 500 simulations 


























Test χ2 test LRT3 LRTest  
1 comp. 2 
comp. 
3 comp. 
0.5 0.5 0.5 0.25 0.9 0.646 0.646 0.59 0.488 0.612 0.642 0.002 0.74 0.258 
0.5 0.5 0.5 0.33 0.9 0.602 0.602 0.568 0.474 0.556 0.624 0.006 0.676 0.318 
0.5 0.5 0.5 0.33 0.5 1 1 1 1 1 0.986 0.014 0.816 0.17 
0.5 0.5 0.5 0.5 0.9 0.446 0.446 0.456 0.336 0.38 0.342 0.196 0.608 0.196 
0.5 0.5 0.5 0.5 0.75 0.986 0.986 0.99 0.972 0.988 0.926 0.068 0.694 0.238 
0.5 0.75 1 0.05 0.9 0.856 0.856 0.642 0.692 0.75 0.91 0 1 0 
0.5 0.75 1 0.05 0.75 1 1 1 0.906 0.99 1 0 1 0 
0.5 0.75 1 0.05 0.5 1 1 1 0.89 1 1 0 1 0 
0.5 0.75 1 0.1 0.9 0.762 0.762 0.62 0.542 0.614 0.778 0 1 0 
0.5 0.75 1 0.1 0.75 1 1 1 0.812 0.968 1 0 1 0 
0.5 0.75 1 0.1 0.5 1 1 1 0.838 1 1 0 1 0 
0.5 0.5 0.5 0.05 0.9 0.896 0.896 0.784 0.848 0.912 0.966 0 1 0 
0.5 0.5 0.5 0.1 0.9 0.816 0.816 0.7 0.664 0.746 0.852 0 1 0 
0.5 0.75 1 0.25 0.9 0.546 0.546 0.482 0.29 0.434 0.508 0 1 0 
0.5 0.75 1 0.25 0.75 1 1 1 0.934 0.99 0.992 0 1 0 
0.5 0.75 1 0.33 0.9 0.462 0.462 0.412 0.298 0.402 0.464 0 0.996 0.004 
0.5 0.75 1 0.33 0.75 0.998 0.998 0.996 0.924 0.98 0.984 0 0.99 0.01 
0.5 0.75 1 0.5 0.9 0.326 0.326 0.308 0.196 0.238 0.264 0 0.452 0.548 
0.5 0.75 1 0.5 0.75 0.938 0.938 0.942 0.828 0.89 0.904 0 0.454 0.546 
0.25 0.375 0.5 0.25 0.9 0.736 0.736 0.614 0.236 0.658 0.654 0 1 0 
0.25 0.375 0.5 0.25 0.75 1 1 1 0.256 1 1 0 0.928 0.072 
0.25 0.375 0.5 0.33 0.9 0.658 0.658 0.566 0.542 0.596 0.596 0 0.002 0.998 
0.25 0.375 0.5 0.5 0.9 0.492 0.492 0.49 0.37 0.4 0.4 0 0 1 
0.25 0.375 0.5 0.5 0.75 0.998 0.998 0.998 0.986 0.998 0.998 0 0 1 






0.25 0.25 0.25 0.33 0.9 0.696 0.696 0.586 0.686 0.692 0.692 0 0 1 
0.25 0.25 0.25 0.5 0.9 0.516 0.516 0.5 0.508 0.502 0.502 0 0 1 
0.25 0.25 0.25 0.05 0.9 0.992 0.992 0.906 0.086 0.586 1 0 1 0 
0.25 0.25 0.25 0.05 0.75 1 1 1 0 0.876 1 0 1 0 
0.25 0.25 0.25 0.05 0.5 1 1 1 0.282 1 1 0 1 0 
0.25 0.25 0.25 0.1 0.9 0.956 0.956 0.848 0.002 0.862 0.972 0 1 0 
0.25 0.25 0.25 0.1 0.75 1 1 1 0 0.978 1 0 1 0 
0.25 0.25 0.25 0.1 0.5 1 1 1 0.066 1 1 0 1 0 
0.25 0.375 0.5 0.05 0.9 0.984 0.984 0.84 0.01 0.634 0.99 0 1 0 
0.25 0.375 0.5 0.05 0.75 1 1 1 0 0.904 1 0 1 0 
0.25 0.375 0.5 0.05 0.5 1 1 1 0 1 1 0 1 0 
0.25 0.375 0.5 0.1 0.9 0.934 0.934 0.792 0 0.826 0.934 0 1 0 
0.25 0.375 0.5 0.1 0.75 1 1 1 0 0.966 1 0 1 0 
0.25 0.375 0.5 0.1 0.5 1 1 1 0.206 1 1 0 1 0 
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D9D C16 0.07 0.03 0.07 0.03 0.07 0.02 
D9D C18 1.27 0.36 1.3 0.4 1.24 0.31 
D9D 16:18 0.05 0.01 0.05 0.01 0.05 0.01 
ELOVL6 0.66 0.12 0.64 0.13 0.67 0.11 
ELOVL6 mono 0.08 0.03 0.08 0.03 0.08 0.03 
FADS2 0.03 0.01 0.03 0.01 0.03 0.01 
ELOVL5 4.38 1.37 4.75 1.41 4.02 1.22 
FADS5 8.43 2.45 8.49 2.63 8.38 2.25 
ELOVL2 n3 3.61 1.33 4.04 1.21 3.19 1.3 
ELOVL2 n6 0.19 0.04 0.2 0.04 0.18 0.04 
ELOVL2 n3:n6 18.93 5.39 20.5 4.8 17.37 5.48 
SCSn6 0.22 0.05 0.23 0.05 0.22 0.05 
SCSn3 1.86 0.63 1.76 0.57 1.96 0.67 




Supplemental Table 6 
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Supplemental Table 7a: Fitting finite normal (log-normal) mixture models using BIC EQUAL 
VARIANCE 
 Norm_1 Norm_2 Norm_3 
D9D C16 6840 7104 7090 
D9D C18 -1236 -984 -999 
D9D 16:18 8911 9122 9107 
ELOVL6 2067 2051 2051 
ELOVL6 mono 6335 6703 6688 
FADS2 10721 10948 10934 
ELOVL5 -5287 -5210 -5226 
FADS5 -7092 -7034 -7049 
ELOVL2 n3 -5217 -5226 -5214 
ELOVL2 n6 5745 5729 5722 
ELOVL2 n3:n6 -9501 -9515 -9496 
SCSn6 4742 4839 4824 
SCSn3 -2943 -2743 -2758 
SCS n3:n6 -8169 -7857 -7871 
 
MClust (R package) was used to assess the fit (using BIC) of a single or multiple component (up to 3) 
Gaussian model for a total of 3 models fit to each of the 14 FA ratios. The model giving the larger BIC 
is highlighted in yellow. 
Using the guidelines of Raftery (1995) for comparing model BIC’s 
 FAs with very strong evidence (diff in BIC of >10; like p<0.006): D9D-C16, D9D-C18, D9D-C16-C18, 
ELOVL6, ELOVL6-mono, FADS2, ELOVl5, FADS5, ELOVL2_N6, SCS-N3, SCS-N6, SCS-N3-N6 
FAs with strong evidence (diff in BIC 6-10; like 0.006<p<0.05): NONE 





Supplemental Table 7b: Fitting finite normal (log-normal) mixture models using BIC EQUAL 
VARIANCE (after removal of the most extreme 0.5% of values in the sample) 
 
Norm_1 Norm_2 Norm_3 
D9D C16 6919 7180 7165 
D9D C18 -1146 -901 -916 
D9D 16:18 8972 9165 9150 
ELOVL6 2140 2127 2121 
ELOVL6 mono 6425 6777 6762 
FADS2 10839 11047 11032 
ELOVL5 -5191 -5116 -5133 
FADS5 -6939 -6883 -6900 
ELOVL2 n3 -5126 -5131 -5124 
ELOVL2 n6 5783 5769 5764 
ELOVL2 n3:n6 -9349 -9359 -9362 
SCSn6 4839 4923 4907 
SCSn3 -2833 -2652 -2667 
SCS n3:n6 -8018 -7722 -7737 
All best fitting models were the same as without the most extreme values. 
33 
 





Supplemental Figure 1b 
General 
Activity 
Non-essential fatty acid metabolism Essential fatty acid metabolism 
Activity 
desaturase 
PA: n7 position 
SA: n9 position 
elongase 
16 carbon FAs 
to eicosanoids to docosanoids 




































Abbreviation D9D C16 
D9D 
C18 
D9D 16:18 ELOVL6 
ELOVL6 
mono 













   
35 































Percent of cases based on risk score 
36 
References 
1. Assmann G, Cullen P, & Schulte H (2002) Simple scoring scheme for calculating the risk of 
acute coronary events based on the 10-year follow-up of the prospective cardiovascular 
Munster (PROCAM) study. Circulation 105(3):310-315. 
2. De Backer G, et al. (2004) European guidelines on cardiovascular disease prevention in 
clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular 
Disease Prevention in Clinical Practice (constituted by representatives of eight societies and 
by invited experts). Atherosclerosis 173(2):381-391. 
3. Chambless LE, et al. (2003) Coronary heart disease risk prediction in the Atherosclerosis 
Risk in Communities (ARIC) study. Journal of clinical epidemiology 56(9):880-890. 
4. Ridker PM, Paynter NP, Rifai N, Gaziano JM, & Cook NR (2008) C-Reactive Protein and 
Parental History Improve Global Cardiovascular Risk Prediction. The Reynolds Risk Score 
for Men. Circulation. 
5. Ridker PM, Buring JE, Rifai N, & Cook NR (2007) Development and validation of improved 
algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk 
Score. Jama 297(6):611-619. 
6. D'Agostino RB, Sr., et al. (2008) General cardiovascular risk profile for use in primary care: 
the Framingham Heart Study. Circulation 117(6):743-753. 
7. Wilson PW, et al. (1998) Prediction of coronary heart disease using risk factor categories. 
Circulation 97(18):1837-1847. 
8. Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical 
considerations. Circulation 113(19):2335-2362. 
9. Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk 
prediction. Circulation 115(7):928-935. 
10. Cook NR (2008) Statistical evaluation of prognostic versus diagnostic models: beyond the 
ROC curve. Clinical chemistry 54(1):17-23. 
11. Lloyd-Jones DM, Liu K, Tian L, & Greenland P (2006) Narrative Review: Assessment of C-
Reactive Protein in Risk Prediction for Cardiovascular Disease. Ann Intern Med. 
12. Folsom AR, et al. (2006) An assessment of incremental coronary risk prediction using C-
reactive protein and other novel risk markers: the atherosclerosis risk in communities study. 
Archives of internal medicine 166(13):1368-1373. 
13. Morgan TM, Krumholz HM, Lifton RP, & Spertus JA (2007) Nonvalidation of reported 
genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 
297(14):1551-1561. 
14. Shearer GC, Pottala JV, Spertus JA, & Harris WS (2009) Red blood cell fatty acid patterns 
and acute coronary syndrome. PloS one 4(5):e5444. 
15. Holmes E, Wilson ID, & Nicholson JK (2008) Metabolic phenotyping in health and disease. 
Cell 134(5):714-717. 
16. Vessby B, Gustafsson IB, Tengblad S, Boberg M, & Andersson A (2002) Desaturation and 
elongation of Fatty acids and insulin action. Ann N Y Acad Sci 967:183-195. 
17. Block RC, Harris WS, Reid KJ, Sands SA, & Spertus JA (2007) EPA and DHA in blood cell 
membranes from acute coronary syndrome patients and controls. Atherosclerosis. 
18. Fraley C, Raferty AE, Murphy TB, & Scrucca L (2012) mclust Version 4 for R: Normal 
Mixture Modeling for Model-Based Clustering, Classification, and Density Estimation 
(Department of Statistics, University of Washington, Seattle, WA), 4. 
19. Kim W, Gordon D, Sebat J, Ye KQ, & Finch SJ (2008) Computing power and sample size 
for case-control association studies with copy number polymorphism: application of 
mixture-based likelihood ratio test. PloS one 3(10):e3475. 
37 
20. Raftery AE (1995) Bayesian model selection in social research. Sociol Methodol 25:111-163. 
21. Mendell NR, Finch SJ, & Thode HC, Jr. (1993) Where is the likelihood ratio test powerful 
for detecting two component normal mixtures? Biometrics 49(3):907-915. 
22. Liu K, Luedtke A, & Tintle N (2013) Optimal methods for using posterior probabilities in 
association testing. Human heredity 75(1):2-11. 
23. Dumas ME (2012) Metabolome 2.0: quantitative genetics and network biology of metabolic 
phenotypes. Molecular bioSystems 8(10):2494-2502. 
24. Shin SY, et al. (2014) An atlas of genetic influences on human blood metabolites. Nat Genet 
46(6):543-550. 
25. Flowers MT & Ntambi JM (2008) Role of stearoyl-coenzyme A desaturase in regulating lipid 
metabolism. Current opinion in lipidology 19(3):248-256. 
26. Jeyakumar SM, et al. (2009) Fatty acid desaturation index correlates with body mass and 
adiposity indices of obesity in Wistar NIN obese mutant rat strains WNIN/Ob and 
WNIN/GR-Ob. Nutrition & metabolism 6:27. 
27. Rhee SK, Kayani AJ, Ciszek A, & Brenna JT (1997) Desaturation and interconversion of 
dietary stearic and palmitic acids in human plasma and lipoproteins. The American journal 
of clinical nutrition 65(2):451-458. 
28. Warensjo E, Sundstrom J, Vessby B, Cederholm T, & Riserus U (2008) Markers of dietary 
fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a 
population-based prospective study. The American journal of clinical nutrition 88(1):203-209. 
29. Green CD & Olson LK (2011) Modulation of palmitate-induced endoplasmic reticulum 
stress and apoptosis in pancreatic beta-cells by stearoyl-CoA desaturase and Elovl6. 
American journal of physiology. Endocrinology and metabolism 300(4):E640-649. 
30. Liu Y, et al. (2013) Genetic analysis of the ELOVL6 gene polymorphism associated with type 
2 diabetes mellitus. Brazilian journal of medical and biological research = Revista brasileira de 
pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 46(7):623-628. 
31. Morcillo S, et al. (2011) ELOVL6 genetic variation is related to insulin sensitivity: a new 
candidate gene in energy metabolism. PloS one 6(6):e21198. 
32. Matsuzaka T, et al. (2012) Elovl6 promotes nonalcoholic steatohepatitis. Hepatology 
56(6):2199-2208. 
33. Aslibekyan S, et al. (2012) Genetic variation in fatty acid elongases is not associated with 
intermediate cardiovascular phenotypes or myocardial infarction. European journal of 
clinical nutrition 66(3):353-359. 
34. Lu Y, et al. (2012) Markers of endogenous desaturase activity and risk of coronary heart 
disease in the CAREMA cohort study. PloS one 7(7):e41681. 
35. Wang L, Folsom AR, & Eckfeldt JH (2003) Plasma fatty acid composition and incidence of 
coronary heart disease in middle aged adults: the Atherosclerosis Risk in Communities 
(ARIC) Study. Nutrition, metabolism, and cardiovascular diseases : NMCD 13(5):256-266. 
 
 
